MYDECINE

Mydecine Innovations Group to Acquire NeuroPharm Inc.

← Back to all news
June 10, 2020

Strategically Positioned on Therapies for Military, Veterans, Front-Line Personnel Globally to cope with Mental Health & Well-Being

VANCOUVER, British Columbia., June 10, 2020 /CNW/ -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce it has signed a non-binding Letter of Intent ("LOI") dated June 9, 2020 to acquire NeuroPharm Inc., ("NeuroPharm") a Canadian-based healthcare company working to deploy the power of nature's medicine for the wellness of veterans, EMS and front line personnel in  North America and globally (the "Acquisition").

"The exceptional roles and responsibilities Canada's military and veterans, EMS and front-line personnel undertake on a daily basis, contribute to these professional's underlying mental health challenges" said Josh Bartch, CEO, Mydecine Innovations Group. "I look forward to working with NeuroPharm's talented clinicians, scientists, academics  and industry leaders focused on responding to these individual's mental health and wellness needs in the years to come."

"Our mission is to build a capability that will truly have a focus on veterans, EMS and other front-line personnel.  This new capability will bring to the table unique skillsets to meet this enormous challenge of building veterans, EMS and front-line staff confidence and restoring their overall wellness. With our experienced team, we understand their unique circumstances related to service that may have contributed to operational stress injuries namely post-traumatic stress disorder (PTSD), depression or anxiety" added Colonel (Ret'd) Pucci, Chairman and CEO NeuroPharm Inc.

Mydecine and NeuroPharm will combine to focus on an integrated health and wellness research strategy and the development of products underpinned by therapies to assist veterans with mental health issues. NeuroPharm is focused on developing unique pharmaceutical and natural health products for veteran wellness , with a specific focus on the use of psilocybin. Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms. Once ingested, psilocybin is rapidly metabolized to psilocin, which then acts on serotonin receptors in the brain. NeuroPharm has developed unique and proprietary technology to treat various mental health conditions that are frequently experienced by veterans such as PTSD, depression, addiction, anxiety, and panic disorders as well as migraine and cluster headaches. Preliminary studies from institutions including the Imperial College of London, University of Zurich, Johns Hopkins, NYU, and UCLA suggest that psilocybin-assisted therapy could be a revolutionary treatment for depression and addiction.

NeuroPharm – Executive Management

The key to NeuroPharm's unique position is  its stewardship, which has extensive established relationships with  global military organizations, as well as an experienced cross-functional team poised to oversee all areas of the product life cycle, from medical mushroom cultivation, drug delivery system development, clinical trial execution, through to product commercialization and marketing:

President and Chief Executive Officer, Colonel (Ret'd) Richard Pucci, OMM, CD, BSc, MDS, served as the Deputy Commander of the Canadian Forces Health Services, during which time he oversaw a team of approximately 6,400 active members and 500 contractors; during his tenure he was responsible for over watching via the chain of command 43 units and 82 detachments, including clinics, mobile medical units, field hospital, schools, research establishment, and a medical equipment depot. He also held the position of Chief of Staff of the Health Services Group, with the overall responsibility for a financial and business planning cycle of $462 million, and an infrastructure budget of $600 million. Colonel (Ret'd) Pucci's knowledge and affiliations within the military community provide additional pathways to unique funding sources and facilitate the development of psilocybin-based treatments for the veterans population.

NeuroPharm – Medical and Scientific Advisory Board

Dr. Rakesh Jetly, OMM, CD, MD, FRCPC, part of the Company's Medical & Scientific Advisory Board, is currently the Head of the Centre of Excellence on Mental Health in Ottawa, Ontario, and an associate professor of psychiatry at Dalhousie University (Halifax); and the University of Ottawa. He has published numerous articles in professional journals and presents nationally and internationally on such topics as PTSD and operational psychiatry.

Dr. Mohyuddin Mirza, PhD, P.Ag, Chief Science Officer, holds a Ph.D. from the University of Alberta and served as an adjunct professor at his alma matter. He was inducted into the Alberta Agriculture Hall of Fame and, subsequently, the Alberta Greenhouse Growers Association created the "Dr. Mohyuddin Mirza Educational and Scholarship Foundation". Dr. Mirza brings with him his vast knowledge of greenhouse technologies, infrastructure, feasibility, research, and development to the NeuroPharm team.

Prof. dr. H.G.J.M. (Eric) Vermetten MD, PhD, is professor Medical-Biological and Psychiatric Aspects of Psych trauma, LUMC/University of Leiden.  Eric Vermetten is psychiatrist at the MGGZ in Utrecht (Military Mental Health care). From 1991 he has been linked to several universities as a researcher, including Stanford University, California, Yale Univ, New Haven CT, Emory Univ, Atlanta, and studied at the University of Maastricht and followed several postgraduate courses. In 2003, Eric was promoted on Posttraumatic Stress Disorders: Neurobiological Studies in the Aftermath of Traumatic Stress at the University of Utrecht. Vermetten considers PTSD a heterogeneous disorder, with different contributions of neurobiological systems and circuits. He is convinced that longitudinal cohort studies, more than research with cross-sectional designs, is important to obtain knowledge breakthroughs. And assumes that in the psych traumatology computer-assisted technology, the patient can give more influence on therapeutic - and care processes.